Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Zymeworks Inc (NY: ZYME )

6.140 +0.150 (+2.50%)
Streaming Delayed Price Updated: 2:31 PM EDT, May 23, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,061,470
Open 5.990
Bid (Size) 6.130 (1)
Ask (Size) 6.140 (3)
Prev. Close 5.990
Today's Range 5.832 - 6.170
52wk Range 4.560 - 39.41
Shares Outstanding 57,771,204
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Zymeworks Turns Down All Blue's Hostile Bid
Zymeworks Inc's (NYSE: ZYME) board has officially turned down an unsolicited, opportunistic, non-binding proposal from an activist shareholder, All Blue Falcons. 
Via Benzinga
Zymeworks’ Board of Directors Unanimously Rejects Unsolicited, Non-Binding Proposal
From Zymeworks Inc.
Via Business Wire

Performance

YTD
-63.84%
-63.84%
1 Month
+26.08%
+26.08%
3 Month
-13.15%
-13.15%
6 Month
-69.21%
-69.21%
1 Year
-78.71%
-78.71%

More News

Read More
Market Selloff
Via Talk Markets
Where Zymeworks Stands With Analysts
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2022
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Zymeworks Provides Corporate Update and Reports First Quarter 2022 Financial Results
From Zymeworks Inc.
Via Business Wire
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Via Benzinga
Earnings Scheduled For May 4, 2022
Via Benzinga
Short Squeeze Stocks: HCDI, ZYME and 3 Others Experts Think Are Ready to Pop
Via InvestorPlace
5 Short Squeeze Candidates To Watch This Week: Aterian, Harbor Custom Development Remain At The Top, Veru Joins
Via Benzinga
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Is Zymeworks (ZYME) Stock Surging 30% Today?
Via InvestorPlace
70 Biggest Movers From Friday
Via Benzinga
Mid-Morning Market Update: Markets Down; Nasdaq Falls 100 Points
Via Benzinga
48 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
The Daily Biotech Pulse: FDA Approves Bristol Myers' Oral Heart Disease Drug, European Approval For Merck's Keytruda, Genocea Restructures, Zymeworks' Takeover Bid
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
28 Stocks Moving in Friday's Pre-Market Session
Via Benzinga
Zymeworks Confirms Receipt of Unsolicited, Non-Binding Proposal from All Blue Falcons
From Zymeworks Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Zymeworks Reports Last Patient Enrolled in Pivotal Study of Zanidatamab in Treatment of HER2-Expressing Late-Line Biliary Tract Cancer
From Zymeworks Inc.
Via Business Wire
Zymeworks Announces Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
From Zymeworks Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.